TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The study is a first-in-human [FIH], open-label phase 1/2 study of TSN222 in subjects with
advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and
Phase 2 dose expansion component.